Novoheart and AstraZeneca agreed on a collaboration to develop the world’s first human-specific in vitro, functional model of heart failure with preserved ejection fraction (HFpEF), a common condition especially among the elderly and in women.
Zelnorm was relaunched by Alfasigma USA for the treatment of irritable bowel syndrome with constipation (IBS-C).
GlaxoSmithKline Plc’s cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said.
Join the HBA for a unique discussion regarding “balance,” the overarching theme for International Women’s Day 2019.
